We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Tag: PCSK9 inhibitor
MedXY News
EnglishTag

PCSK9 inhibitor

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

Evolocumab Significantly Reduces Mortality in High-Risk Patients Without Prior Heart Attack or Stroke: Insights from the VESALIUS-CV Trial
CardiologyPCSK9 inhibitorEvolocumab

Evolocumab Significantly Reduces Mortality in High-Risk Patients Without Prior Heart Attack or Stroke: Insights from the VESALIUS-CV Trial

By MedXY|Sep 8, 2026

The VESALIUS-CV trial demonstrates that evolocumab lowers all-cause and cardiovascular mortality in patients with high cardiovascular risk but no prior myocardial infarction or stroke, highlighting its survival benefits in primary preventio

Enlicitide: A Breakthrough Oral PCSK9 Inhibitor Offering Superior LDL-C Reduction Compared to Established Oral Nonstatin Therapies
Cardiology
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
enlicitide
Nonstatin lipid-lowering therapy

Enlicitide: A Breakthrough Oral PCSK9 Inhibitor Offering Superior LDL-C Reduction Compared to Established Oral Nonstatin Therapies

By MedXY|Aug 18, 2026

This phase 3 trial demonstrates that the oral PCSK9 inhibitor enlicitide achieves significantly greater LDL-C reduction than bempedoic acid, ezetimibe, or their combination in statin-treated adults at elevated cardiovascular risk, with comp

Evolocumab in Patients With Prior Percutaneous Coronary Intervention and No Prior MI: Results From the VESALIUS-CV Trial
Cardiologycoronary artery diseaseEvolocumab

Evolocumab in Patients With Prior Percutaneous Coronary Intervention and No Prior MI: Results From the VESALIUS-CV Trial

By MedXY|May 19, 2026

In patients with prior PCI but no prior MI, evolocumab significantly lowered LDL-C and reduced major cardiovascular events, including myocardial infarction and urgent revascularization, supporting intensive lipid lowering after coronary int

Laroprovstat, the First Oral Small-Molecule PCSK9 Inhibitor for Hypercholesterolemia: Results From a Phase 1 Trial
Cardiologycardiovascular riskHypercholesterolemia

Laroprovstat, the First Oral Small-Molecule PCSK9 Inhibitor for Hypercholesterolemia: Results From a Phase 1 Trial

By MedXY|May 15, 2026

Laroprovstat, an investigational oral PCSK9 inhibitor, was well tolerated and produced substantial LDL cholesterol reductions, especially when combined with rosuvastatin, supporting further development for hypercholesterolemia.

PCSK9 Inhibition Lowers LDL Cholesterol in Heterozygous Familial Hypercholesterolemia Regardless of LDL Receptor Variant Function
CardiologyFamilial HypercholesterolaemiaLDL Cholesterol

PCSK9 Inhibition Lowers LDL Cholesterol in Heterozygous Familial Hypercholesterolemia Regardless of LDL Receptor Variant Function

By MedXY|May 3, 2026

In a pooled nonrandomized phase 3 analysis, monthly lerodalcibep reduced LDL-C by about 50% in heterozygous familial hypercholesterolemia, with similar efficacy across LDLR functional variant categories and broad attainment of guideline-bas

Evolocumab Prevents First Major Cardiovascular Events in High‑Risk Patients without Prior MI or Stroke
CardiologyEvolocumabMACE

Evolocumab Prevents First Major Cardiovascular Events in High‑Risk Patients without Prior MI or Stroke

By MedXY|Nov 13, 2025

In VESALIUS-CV, evolocumab reduced first major adverse cardiovascular events by ~25% (HR 0.75) versus placebo in patients with atherosclerosis or diabetes without prior myocardial infarction or stroke, with modest absolute risk reductions a

Evolocumab’s Impact on Cardiovascular Risk in Type 1 Diabetes: Insights from the FOURIER Trial
Cardiologycardiovascular outcomesEvolocumab

Evolocumab’s Impact on Cardiovascular Risk in Type 1 Diabetes: Insights from the FOURIER Trial

By MedXY|Oct 4, 2025

The FOURIER trial reveals intensive LDL-C lowering with evolocumab substantially reduces cardiovascular events in type 1 diabetes patients with ASCVD, highlighting significant clinical benefit and urging further dedicated research.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities